Featured Story | By Max Bayer ARCH Venture Partners has raised nearly $3 billion in a new venture fund, a glimmer of hope as biotechs large and small lick their wounds amid a market downturn that's lasted more than a year. The early investment firm was able to secure roughly a billion more dollars this time around compared to its previous fund. read more |
| |
|---|
|
Top Stories By Annalee Armstrong As Genentech’s Greg Rippon, M.D., detailed his company’s failed Alzheimer’s disease study, his fellow panelists nodded solemnly. They’d all been there before. read more By Max Bayer FDA advisers voted 19-2 on Tuesday to recommend incorporating the omicron variant into future vaccine compositions. What exactly those compositions look like will be left to the FDA. read more By Nick Paul Taylor Astellas has ventured off the beaten path for its latest R&D deal, heading to Pittsburgh to partner with low-profile Generian on the discovery of small molecules against undruggable targets. The pact pairs Generian with Mitobridge, an Astellas unit focused on compounds that target mitochondrial function. read more By James Waldron Big Pharma has long touted the game-changing potential of artificial intelligence to improve drug development. But what does it mean in practice? read more By Gabrielle Masson ReCode Therapeutics has stuck to a formula of $80 million funding rounds, but thanks to investments from the venture arms of Bayer and Amgen, the genetic medicine and mRNA biotech is breaking the mold with a $120 million extended series B. read more By Nick Paul Taylor Medicxi, OrbiMed and other VCs have joined forces to help MiroBio flip immune checkpoint R&D on its head, committing $97 million to support development of BTLA and PD-1 autoimmune programs that put the British biotech on turf targeted by AnaptysBio and Eli Lilly. read more By Annalee Armstrong Regulatory efforts were finally rolling along at Santhera Pharmaceuticals for its Duchenne muscular dystrophy treatment. But now, a manufacturing snag has set the timeline for an FDA inspection back, and the company will need to go back to the agency to figure out a new timeline. read more By James Waldron 89bio has hailed mid-stage data as proof that its prospective NASH drug can also lower high blood lipid levels. A study of the drug, called pegozafermin, met its primary endpoint of demonstrating statistically significant reductions in triglycerides—a type of lipid found in the blood. read more By Gabrielle Masson Bayer has opened a new U.S. cancer research and innovation center at the tune of $140 million—a move that will add 50 new jobs—as the German pharma attempts to become a top 10 oncology company by 2030. read more By Gareth Macdonald Clinical trials are generating more data than ever and researchers need systems capable of recording, storing and managing the additional information, says tech firm Medidata. read more By Conor Hale Bayer is diving into the radiology AI market, which the drugmaker estimates will grow by more than 25% per year between now and 2025. read more By Conor Hale Merck has begun taking applications for a new biotech accelerator program and is on the hunt for startups offering a special focus on artificial intelligence and machine learning. read more Resources Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored By: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Blue Matter, strategic consultants in the life sciences Medical Affairs plays a critical role in generating insights to inform strategic decisions, but that role is changing. This paper explores why, and how MA teams can stay ahead of the curve. Sponsored By: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
